Infectious DiseasePfizer
Pfizer Reports Paxlovid Maintains Efficacy Against New COVID-19 Variants
BMI
Biotechnology Media Insights
Editorial Team · July 5, 2025
Pfizer announces new data showing Paxlovid (nirmatrelvir/ritonavir) retains antiviral activity against emerging SARS-CoV-2 variants including JN.1 and KP.2.
Pfizer today announced new in vitro and clinical data showing that Paxlovid (nirmatrelvir/ritonavir) maintains potent antiviral activity against emerging SARS-CoV-2 variants, including JN.1, KP.2, and other Omicron subvariants.
BMI
Biotechnology Media Insights
Published by Biotechnology Media Insights — your trusted source for pharmaceutical, biotech, and life sciences news.